Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Ionis Pharma Plummets After GlaxoSmithKline Opts Not to Initiate Phase III Study for Amyloid Cardiomyopathy Drug

Shares of Ionis Pharmaceuticals were down more than 35 percent after its partner GlaxoSmithKline opted to not initiate a Phase III study of its IONIS-TTR drug program for the treatment of patients with TTR amyloidosis.

Read More »

Theranos Now Faces Consumer Class Action Lawsuit

The first lawsuit against embattled blood-testing company Theranos has been filed since the company announced it had invalidated two years of test results.

Read More »

U.S. panel backs approval of Sanofi combination diabetes drug

A U.S. advisory panel recommended approval of a new diabetes drug made by Sanofi SA.

Read More »

Concussions tied to more school problems than other injuries

High school and college students who get concussions may struggle more with academics than their peers who get other types of sports injuries, a small U.S. study suggests.

Read More »

Israeli firms team up for high-speed 3D stem cell printing

Israeli 3D printer firm Nano Dimension has successfully lab-tested a 3D bioprinter for stem cells, paving the way for the potential printing of large tissues and organs, the company said.

Read More »

FDA delays decision on Sarepta’s DMD drug

The U.S. FDA deferred a highly anticipated decision on whether to approve Sarepta Therapeutics Inc.’s muscle-wasting disorder drug.

Read More »

Sanofi to unveil challenge to Medivation’s board

France’s Sanofi SA is preparing to name candidates it will put forward to replace the entire board of U.S. cancer drug company Medivation Inc.

Read More »

Omnicom Health Appoints TBWA\WorldHealth Leadership Team

Omnicom Health Group announced the leadership team for TBWA\WorldHealth, the new agency created by the combination of two healthcare specialist agencies, Corbett and LLNS.

Read More »

Sophiris Bio Slashes Workforce in Half as Firm Explores Strategic Options

Although having successfully completed a Phase III trial assessing its urological disease treatment drug, topsalysin (PRX302), San Diego-based Sophiris has slashed half its workforce in an effort to reduce operating expenses before moving forward with a second Phase III trial.

Read More »

Retired Gilead Exec Returns as His Replacement Exits

Kevin Young will return to Gilead Sciences as the company’s chief operating officer, replacing the man who replaced him when he retired. Bringing Young back into an active role with the company may be a signal the company is moving to solidify its position atop the hepatitis market as other companies develop drugs to challenge its blockbuster therapies, Harvoni and Sovaldi.

Read More »

FDA panel recommends approval of Novo Nordisk diabetes drug

A U.S. advisory panel recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combo.

Read More »

Lilly says new type of pain drug could lessen need for opioids

Eli Lilly and Co. said it and partner Pfizer Inc. aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain.

Read More »

Specialists call for gastric surgery to be standard diabetes treatment

Gastric surgery should be offered as a standard treatment option for people with diabetes and could help them control their condition for years without medication, the world’s leading diabetes organizations said.

Read More »

GSK lung drug succeeds in big UK study

GlaxoSmithKline’s new inhaled drug Breo proved significantly better than standard care in a large British study that tested it in everyday use after the failure of another big trial in 2015.

Read More »

Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial

Theratechnologies Inc. announces that it has been notified by its partner, TaiMed Biologics Inc., of the preliminary results for the primary end point of the phase III trial with ibalizumab in patients with multi-drug resistant HIV-1 (TMB-301).

Read More »

Novartis AG CEO Attempts to Rebuild as Seven Execs Jump Ship in the Space of Five Months

Novartis AG has seen a number of high profile executives depart the company since the beginning of the year and more C-suite-level employees are planning to exit as well, Reuters reported.

Read More »

UCB faces U.S. patent challenge for epilepsy drug

The U.S. PTO is to review UCB’s patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharma company and generic rivals.

Read More »

Eli Lilly Projects 20 New Product Launches in 10 Years

Indianapolis-based Eli Lilly and Company is on a roll, announcing that between 2014 and 2023, it may launch 20 new products.

Read More »

Can ADHD appear for the first time in adulthood?

Attention deficit hyperactivity disorder (ADHD), usually diagnosed in children, may show up for the first time in adulthood, two recent studies suggest.

Read More »

U.S. states on Zika’s frontline see big gaps in funding, expertise

The outbreak is expected to reach the continental United States in the coming weeks as temperatures rise and mosquito populations multiply. In interviews with Reuters, more than a dozen state and local health officials and disease control experts say they worry they will have neither the money nor the time to plug gaping holes in the nation’s defenses.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom